Skip to main content
    N

    Nautilus Biotechnology Inc (NAUT)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $2.10
    -0.22 (-9.48%)

    Market Cap: $295.50M

    Last updated: Nov 17, 2026 at 11:06 AM ET

    Nautilus Biotechnology Inc (NAUT) Financials: Revenue, Profit and Cash Flow

    Updated Oct 27, 2026. Financial statements from company filings, amounts in US dollars.

    Nautilus Biotechnology reported revenue of $0 for the fiscal year ended Dec 31, 2025. That year, net income was -$59.00M, operating cash flow was -$50.70M and free cash flow was -$51.97M. The quarter ended Sep 30, 2026 had revenue of $234.00K and net income of -$15.64M.

    Revenue and Margins

    The company reported no revenue in the fiscal year ended Dec 2025, with an operating loss of $66.84M.

    Fiscal yearRevenueGrowthGross marginOperating marginNet margin
    Dec 2025$0N/AN/AN/AN/A
    Dec 2024$0N/AN/AN/AN/A
    Dec 2023$0N/AN/AN/AN/A
    Dec 2022$0N/AN/AN/AN/A
    Dec 2021$0N/AN/AN/AN/A
    Dec 2020$0N/AN/AN/AN/A
    Dec 2019N/AN/AN/AN/AN/A
    Dec 2018N/AN/AN/AN/AN/A
    Annual, fiscal years ended Dec 2018 to Dec 2025

    Income Statement

    In the fiscal year ended Dec 2025, the net loss narrowed from the year before. In the quarter ended Sep 2026, the net loss widened from the same quarter a year earlier.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018
    Research and development$41.11M$50.48M$47.25M$37.67M$29.35M$12.43M$8.49M$0
    Operating income-$66.84M-$81.48M-$76.15M-$63.62M-$50.50M-$15.74M-$10.11M-$111.68M
    Net income-$59.00M-$70.78M-$63.67M-$57.92M-$50.31M-$15.62M-$9.62M$626.60M
    EBITDA-$61.82M-$77.93M-$73.18M-$61.21M-$47.62M-$13.12M-$9.56M$626.60M
    Fiscal years ended Dec 2018 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Revenue$234.00K$190.00K$0$0$0$0$0$9.60M$0$0$0$8.21M
    Gross profit$210.00K$175.00K$0-$1.59M$0$0$0-$6.35M$0$0$0-$1.59M
    Operating income-$16.74M-$15.76M-$16.12M-$15.42M-$15.47M-$17.10M-$18.84M-$19.98M-$19.10M-$20.79M-$21.61M-$20.00M
    Net income-$15.64M-$14.47M-$14.70M-$13.78M-$13.57M-$15.03M-$16.61M-$17.59M-$16.45M-$18.01M-$18.73M-$17.02M
    Last 12 quarters

    Balance Sheet

    As of Dec 2025, cash and equivalents exceeded short-term debt of $3.83M by $8.56M.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018
    Total assets$191.11M$242.74M$305.56M$350.05M$398.45M$85.01M$18.54M$145.82M
    Current assets$105.96M$132.83M$176.84M$187.21M$349.22M$77.66M$16.96M$1.33M
    Cash and equivalents$12.39M$27.65M$19.40M$114.52M$185.62M$36.61M$595.00K$1.20M
    Total liabilities$34.14M$34.01M$40.21M$35.13M$34.87M$6.31M$490.00K$140.82M
    Short-term debt$3.83M$4.10M$3.54M$1.99M$970.00K$1.48MN/AN/A
    Shareholder equity$156.97M$208.73M$265.35M$314.92M$363.58M-$29.72M$18.05M$5.00M
    Fiscal years ended Dec 2018 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Total assets$148.92M$163.58M$177.78M$191.11M$200.91M$213.19M$227.69M$242.74M$259.70M$272.75M$288.65M$305.56M
    Total liabilities$32.37M$32.46M$33.36M$34.14M$31.78M$32.09M$33.26M$34.01M$36.27M$37.47M$39.16M$40.21M
    Cash and equivalents$10.47M$13.17M$14.63M$12.39M$23.88M$34.46M$33.24M$27.65M$4.41M$24.89M$25.73M$19.40M
    Shareholder equity$116.56M$131.11M$144.41M$156.97M$169.14M$181.09M$194.44M$208.73M$223.43M$235.28M$249.49M$265.35M
    Last 12 quarters

    Cash Flow

    Operating cash flow was negative in the fiscal year ended Dec 2025.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018
    Operating cash flow-$50.70M-$59.15M-$51.71M-$45.81M-$39.24M-$14.00M-$9.66M-$238.30M
    Capital expenditures$1.28M$2.12M$2.44M$2.32M$2.27M$921.00K$926.00K$0
    Free cash flow-$51.97M-$61.27M-$54.15M-$48.13M-$41.51M-$14.92M-$10.59M-$238.30M
    Dividends paidN/AN/AN/AN/AN/A$52.95KN/AN/A
    Share repurchasesN/AN/AN/AN/A$8.13M$0N/AN/A
    Investing cash flow$35.22M$66.25M-$43.73M-$25.74M-$138.96M-$25.28M$4.05M$1.20M
    Financing cash flow$214.00K$1.14M$368.00K$562.00K$327.45M$75.90M$36.00K$145.19B
    Fiscal years ended Dec 2018 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Operating cash flow-$13.28M-$13.73M-$13.10M-$12.38M-$11.03M-$13.35M-$13.94M-$14.31M-$13.11M-$15.46M-$16.27M-$13.90M
    Capital expenditures$1.45M$454.00K$510.00K$244.00K$418.00K$396.00K$219.00K$254.00K$709.00K$512.00K$647.00K$413.00K
    Free cash flow-$14.73M-$14.18M-$13.61M-$12.62M-$11.45M-$13.75M-$14.16M-$14.56M-$13.82M-$15.97M-$16.91M-$14.31M
    Last 12 quarters

    Frequently Asked Questions About NAUT

    What is Nautilus Biotechnology's annual revenue?

    Nautilus Biotechnology reported revenue of $0 for the fiscal year ended Dec 31, 2025.

    Is Nautilus Biotechnology profitable?

    No. Nautilus Biotechnology reported net income of -$59.00M for the fiscal year ended Dec 31, 2025.

    How much free cash flow does NAUT generate?

    For the fiscal year ended Dec 31, 2025, operating cash flow of -$50.70M minus capital expenditures of $1.28M produced free cash flow of -$51.97M.

    How much debt does Nautilus Biotechnology have?

    The balance sheet dated Dec 31, 2025 reported short-term debt of $3.83M and cash and equivalents of $12.39M.